Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultralife (ULBI) EBITDA (2016 - 2025)

Ultralife has reported EBITDA over the past 16 years, most recently at -$7.5 million for Q4 2025.

  • Quarterly results put EBITDA at -$7.5 million for Q4 2025, down 930.91% from a year ago — trailing twelve months through Dec 2025 was -$5.0 million (down 184.36% YoY), and the annual figure for FY2025 was -$5.0 million, down 184.36%.
  • EBITDA for Q4 2025 was -$7.5 million at Ultralife, down from -$1.5 million in the prior quarter.
  • Over the last five years, EBITDA for ULBI hit a ceiling of $3.4 million in Q4 2023 and a floor of -$7.5 million in Q4 2025.
  • Median EBITDA over the past 5 years was $774000.0 (2021), compared with a mean of $264789.5.
  • Biggest five-year swings in EBITDA: surged 1884.56% in 2024 and later plummeted 930.91% in 2025.
  • Ultralife's EBITDA stood at -$965000.0 in 2021, then plummeted by 100.0% to -$1.9 million in 2022, then soared by 275.6% to $3.4 million in 2023, then tumbled by 121.48% to -$728000.0 in 2024, then plummeted by 930.91% to -$7.5 million in 2025.
  • The last three reported values for EBITDA were -$7.5 million (Q4 2025), -$1.5 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.